Galapagos strikes a deal to make CAR-T therapies at U.S. blood centers

The deal with Blood Centers of America will open up dozens of manufacturing sites as Galapagos moves its CAR-Ts for different cancers into pivotal studies. 

May 17, 2024 Check out STAT+

Sponsored By

Fran van Delft for Galapagos STAT+ | Galapagos, in makeover mode, strikes deal to make CAR-T therapies at blood centers across U.S. Galapagos said the collaboration could help overcome the limitations that have held back access to CAR-T therapies from other companies. By Andrew Joseph STAT+ | NVIDIA's Kimberly Powell touts progress on AI in drug discovery Readouts from early stage clinical trials show that artificial intelligence is already having an impact on drug discovery, Powell said. By Katherine MacPhail and Mario Aguilar STAT+ | Analysis of pharmaceutical R&D ranks Novo Nordisk and Johnson & Johnson above their peers The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma. By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser